Biogen Inc vs Teradyne, Inc. — how do they compare? Biogen Inc trades at $203.5 (market cap $30.13B), while Teradyne, Inc. trades at $389.5 (market cap $59.34B). The key difference: Teradyne, Inc. is the larger of the two by market cap, and Teradyne, Inc. pays a 0.14% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | TER | |
|---|---|---|
Market Cap | $30.13B | $59.34B |
Sector | Health | Technology |
52-Week High | $216.63 | $483.84 |
52-Week Low | $128.93 | $109.30 |
Enterprise Value | $37.20B | $59.09B |
Dividend Yield | — | 0.14% |
Trailing returns across standard periods
Latest headlines on both assets
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →